Современный взгляд на основные аспекты подготовки пациентов с дифференцированным раком щитовидной железы к радиойодтерапии: научный обзор
- Авторы: Рейнберг М.В.1, Слащук К.Ю.1, Трухин А.А.1, Аврамова К.И.1, Шеремета М.С.1
-
Учреждения:
- Национальный медицинский исследовательский центр эндокринологии
- Выпуск: Том 4, № 4 (2023)
- Страницы: 543-568
- Раздел: Обзоры
- URL: https://ogarev-online.ru/DD/article/view/262966
- DOI: https://doi.org/10.17816/DD532728
- ID: 262966
Цитировать
Аннотация
Рак щитовидной железы — наиболее распространённая опухоль эндокринной системы, составляющая 1–3% всех злокачественных новообразований (по состоянию на 2021 год). В 90% случаев выявляют дифференцированные формы — папиллярный и фолликулярный варианты — обладающие относительно благоприятным прогнозом.
Комбинация хирургического лечения и последующей супрессивной гормональной терапии, радиойодтерапии, обеспечивают благоприятный прогноз у пациентов с высокодифференцированным раком щитовидной железы. Тем не менее сохраняется вероятность недостаточного ответа на радиойодтерапию, что может быть ассоциировано со многими факторами, включая этап подготовки к её проведению. На сегодняшний день сохраняется актуальным вопрос о выборе оптимального метода подготовки пациента к терапии радиоактивным йодом.
В публикации представлен обзор научной литературы, посвящённой аспектам подготовки пациента с высокодифференцированным раком щитовидной железы к проведению терапии радиоактивным йодом. Освещены и обобщены принципы подготовки пациентов на основании рекомендаций ведущих экспертных сообществ и публикаций по данной теме, приняты во внимание нежелательные явления, ассоциированные с радиойодтерапией, качество жизни пациентов, эффективность и отдалённые результаты лечения.
Основная цель обзора — составить целостное представление о методах подготовки пациента с высокодифференцированным раком щитовидной железы к проведению радиойодтерапии, осветить существующие проблемы и перспективные направления исследований с целью модернизации лечения в сторону персонализированной терапии.
Был проведен поиск научных статей и обзоров, опубликованных до конца января 2023 года, в базах данных National Library of Medicine, The Cochrane Library и Google Scholar по следующим ключевым словам: подготовка к радиойодтерапии, тиреотропин альфа, отмена тиреоидных гормонов, побочные эффекты, йод-ограниченная диета, сиалоаденит, первичный гипотиреоз, качество жизни, тиреоидэктомия, дифференцированный рак щитовидной железы, эффективность радиойодтерапии — в их различных комбинациях. Использовались рекомендации по высокодифференцированному раку щитовидной железы следующих научных сообществ: Российские клинические рекомендации по высокодифференцированному раку щитовидной железы, American Thyroid Association, European Thyroid Association, The National Comprehensive Cancer Network, European Association of Nuclear Medicine, British Thyroid Association, European Society for Medical Oncology. Критериями исключения были статьи, не доступные в полном объёме, не на английском или русском языках, систематические обзоры на аналогичную тему. Всего было отобрано и проанализировано 124 источника, выделены общие тенденции современного подхода к подготовке пациентов к терапии радиоактивным йодом и актуальные проблемы, освещены концепции оптимизации подготовки к радиойодтерапии в рамках персонализации терапии, сформированы результаты и выводы.
Полный текст
Открыть статью на сайте журналаОб авторах
Мария Валентиновна Рейнберг
Национальный медицинский исследовательский центр эндокринологии
Автор, ответственный за переписку.
Email: mrezerford12@gmail.com
ORCID iD: 0009-0002-1632-2197
ResearcherId: IUO-4237-2023
Россия, Москва
Константин Юрьевич Слащук
Национальный медицинский исследовательский центр эндокринологии
Email: slashuk911@gmail.com
ORCID iD: 0000-0002-3220-2438
SPIN-код: 3079-8033
канд. мед. наук
Россия, МоскваАлексей Андреевич Трухин
Национальный медицинский исследовательский центр эндокринологии
Email: Alexey.trukhin12@gmail.com
ORCID iD: 0000-0001-5592-4727
SPIN-код: 4398-9536
канд. техн. наук
Россия, МоскваКарина Игоревна Аврамова
Национальный медицинский исследовательский центр эндокринологии
Email: dravramovak@gmail.com
ORCID iD: 0009-0008-4970-8911
SPIN-код: 4330-0263
Россия, Москва
Марина Сергеевна Шеремета
Национальный медицинский исследовательский центр эндокринологии
Email: marina888@yandex.ru
ORCID iD: 0000-0003-3785-0335
SPIN-код: 7845-2194
канд. мед. наук
Россия, МоскваСписок литературы
- Ванушко В.Э., Цуркан А.Ю. Лечение дифференцированного рака щитовидной железы: состояние проблемы // Клиническая экспериментальная тиреоидология. 2010. Т. 6, № 2. С. 24–33. doi: 10.14341/ket20106224-33
- Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва : МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022.
- Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy // The Journal of Clinical Endocrinology & Metabolism. 2006. Vol. 91, N 8. P. 2892–2899. doi: 10.1210/jc.2005-2838
- Cancer Stat Facts: Thyroid Cancer [Internet]. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. [дата обращения: 01.09.2023]. Доступ по ссылке: https://seer.cancer.gov/statfacts/html/thyro.html
- Braverman L.E., Cooper D.S., Kopp P. Werner & Ingbar’s The Thyroid: A Fundamental and Clinical Text. 11th ed. // Philadelphia, PA : Wolters Kluwer, 2021.
- Hassan A., Razi M., Riaz S., et al. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan // Clinical Nuclear Medicine. 2016. Vol. 41, N 8. P. 606–613. doi: 10.1097/RLU.0000000000001237
- Клинические рекомендации — Дифференцированный рак щитовидной железы. ID 329. Одобрено Научно-практическим Советом Минздрава РФ. 2020. Режим доступа: https://cr.minzdrav.gov.ru/recomend/329_1 Дата обращения: 1.09.2023
- Avram A.M., Giovanella L., Greenspan B., et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version // Journal of Nuclear Medicine. 2022. Vol. 63, N 6. P. 15N–35N.
- Haugen B.R., Alexander E.K., Bible K.C., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer // Thyroid. 2016. Vol. 26, N 1. P. 1–133. doi: 10.1089/thy.2015.0020
- Pacini F., Fuhrer D., Elisei R., et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? // European Thyroid Journal. 2022. Vol. 11, N 1. doi: 10.1530/etj-21-0046
- Filetti S., Durante C., Hartl D., et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. 2019. Vol. 30, N 12. P. 1856–1883. doi: 10.1093/annonc/mdz400
- Perros P., Boelaert K., Colley S., et al. Guidelines for the management of thyroid cancer // Clinical Endocrinology. 2014. Vol. 81, Suppl. 1. P. 1–122. doi: 10.1111/cen.12515
- Haddad R.I., Bischoff L., Ball D., et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology // Journal of the National Comprehensive Cancer Network. 2022. Vol. 20, N 8. P. 925–951. doi: 10.6004/jnccn.2022.0040
- Golger A., Fridman T.R., Eski S., et al. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma // Journal of Endocrinological Investigation. 2003. Vol. 26, N 10. P. 1023–1031. doi: 10.1007/bf03348202
- Davids T., Witterick I.J., Eski S., et al. Three-Week Thyroxine Withdrawal: A Thyroid-Specific Quality of Life Study // The Laryngoscope. 2006. Vol. 116, N 2. P. 250–253. doi: 10.1097/01.mlg.0000192172.61889.43
- Lee J., Yun M.J., Nam K.H., et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma // Thyroid. 2010. 2010. Vol 20. P. 173-179. doi: 10.1089/thy.2009.0187
- Leboeuf R., Perron P., Carpentier A.C., Verreault J., Langlois M.F. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial // Clinical Endocrinology. 2007. Vol. 67, N 6. P. 839–844. doi: 10.1111/j.1365-2265.2007.02972.x
- Rajamanickam S., Chaukar D., Siddiq S., Basu S., D’Cruz A. Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population // European Archives of Oto-Rhino-Laryngology. 2021. Vol. 279, N 4. doi: 10.1007/s00405-021-06948-6
- Luna R., Penín M., Seoane I., et al. ¿Es necesario suspender durante 4 semanas el tratamiento con tiroxina antes de la realización de un rastreo-ablación? // Endocrinología y Nutrición. 2012. Vol. 59, N 4. P. 227–231. (In Spanish) doi: 10.1016/j.endonu.2012.02.004
- Dow K.H., Ferrell B.R., Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy // Thyroid. 1997. Vol. 7, N 4. P. 613–619. doi: 10.1089/thy.1997.7.613
- Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients // Clinical Endocrinology. 2002. Vol. 57, N 4. P. 523–527. doi: 10.1046/j.1365-2265.2002.01631.x
- Piccardo A., Puntoni M., Ferrarazzo G., et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? // European Journal of Nuclear Medicine and Molecular Imaging. 2018. Vol. 45, N 7. P. 1218–1223. doi: 10.1007/s00259-018-3955-x
- Santos P.A., Flamini M.E., Mourato F.A., et al. Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment // Brazilian Journal of Radiation Sciences. 2022. Vol. 10, N 4. P. 1–16. doi: 10.15392/2319-0612.2022.2047
- Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. 2009. Vol. 19, N 11. P. 1167–1214. doi: 10.1089/thy.2009.0110
- Rosário P.W., Vasconcelos F.P., Cardoso L.D., et al. Managing thyroid cancer without thyroxine withdrawal // Arquivos Brasileiros de Endocrinologia & Metabologia. 2006. Vol. 50, N 1. P. 91–96. doi: 10.1590/s0004-27302006000100013
- Edmonds C.J., Hayes S., Kermode J.C., Thompson B.D. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine // The British Journal of Radiology. 1977. Vol. 50, N 599. P. 799–807. doi: 10.1259/0007-1285-50-599-799
- Giovanella L., Piccardo A. A “new/old method” for TSH stimulation: could a third way to prepare DTC patients for 131I remnant ablation possibly exist? // European Journal of Nuclear Medicine and Molecular Imaging. 2015. Vol. 43, N 2. P. 221–223. doi: 10.1007/s00259-015-3245-9
- Семенов Д.Ю., Борискова М.Е., Фарафонова У.В., и др. Прогностическое значение экспрессии натрий-йодного симпортера для высокодифференцированного рака щитовидной железы // Клиническая и экспериментальная тиреоидология. 2015. Т. 11, № 1. С. 50. doi: 10.14341/ket2015150-58
- Xiao J., Yun C., Cao J., et al. A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients // Scientific Reports. 2021. Vol. 11, N 1. doi: 10.1038/s41598-020-80015-8
- Zhao T., Liang J., Guo Z., Li T., Lin Y. In Patients with Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy // Clinical Nuclear Medicine. 2016. Vol. 41, N 6. P. 454–458. doi: 10.1097/rlu.0000000000001167
- Hasbek Z., Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success? // Molecular Imaging and Radionuclide Therapy. 2016. Vol. 25, N 2. P. 79–84. doi: 10.4274/mirt.88598
- Vrachimis A., Riemann B., Mäder U., Reiners C., Verburg F.A. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality // European Journal of Nuclear Medicine and Molecular Imaging. 2016. Vol. 43, N 2. P. 224–231. doi: 10.1007/s00259-015-3223-2
- Montesano T., Durante C., Attard M., et al. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer // Biomedicine & Pharmacotherapy. 2007. Vol. 61, N 8. P. 468–471. doi: 10.1016/j.biopha.2007.04.001
- Ju N., Hou L., Song H., et al. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer // European Thyroid Journal. 2023. Vol. 12, N 4. doi: 10.1530/ETJ-22-0219
- Ren B., Zhu Y. A New Perspective on Thyroid Hormones: Crosstalk with Reproductive Hormones in Females // International Journal of Molecular Sciences. 2022. Vol. 23, N 5. P. 2708. doi: 10.3390/ijms23052708
- Rubio G.A., Catanuto P., Glassberg M.K., Lew J.I., Elliot S.J. Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause // Surgery. 2018. Vol. 163, N 1. P. 143–149. doi: 10.1016/j.surg.2017.04.031
- Derwahl M., Nicula D. Estrogen and its role in thyroid cancer // Endocrine-Related Cancer. 2014. Vol. 21, N 5. P. T273–T283. doi: 10.1530/erc-14-0053
- Rajoria S., Suriano R., Shanmugam A., et al. Metastatic phenotype is regulated by estrogen in thyroid cells // Thyroid. 2010. Vol. 20, N 1. P. 33–41. doi: 10.1089/thy.2009.0296
- Tala H., Robbins R., Fagin J.A., Larson S.M., Tuttle R.M. Five-year survival is similar thyroid cancer patients with metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH // The Journal of Clinical Endocrinology & Metabolism. 2011. Vol. 96, N 7. P. 2105–2111. doi: 10.1210/jc.2011-0305
- Rosario P.W., Mourão G.F., Calsolari M.R. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b) // Archives of Endocrinology and Metabolism. 2017. Vol. 61, N 2. P. 167–172. doi: 10.1590/2359-3997000000247
- Hugo J., Robenshtok E., Grewal R., Larson S., Tuttle R.M. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence // Thyroid. 2012. Vol. 22, N 10. P. 1007–1015. doi: 10.1089/thy.2012.0183
- Robenshtok E., Tuttle R.M. Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer // Indian Journal of Surgical Oncology. 2012. Vol. 3, N 3. P. 182–189. doi: 10.1007/s13193-011-0115-1
- Higuchi C.R.S., Fernanda P., Jurnior P.A., et al. Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence // Frontiers in Nuclear Medicine. 2021. Vol. 1. doi: 10.3389/fnume.2021.785768
- Lawhn-Heath C., Flavell R.R., Chuang E.Y., Liu C. Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation // World Journal of Nuclear Medicine. 2020. Vol. 19, N 1. P. 61–64. doi: 10.4103/wjnm.WJNM_29_19
- Lee H., Paeng J.C., Choi H., et al. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration // PLoS One. 2021. Vol. 16, N 9. P. e0256727. doi: 10.1371/journal.pone.0256727
- Driedger A.A., Kotowycz N. Two Cases of Thyroid Carcinoma That Were Not Stimulated by Recombinant Human Thyrotropin // The Journal of Clinical Endocrinology & Metabolism. 2004. Vol. 89, N 2. P. 585–590. doi: 10.1210/jc.2003-031650
- Mernagh P., Campbell S., Dietlein M., et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective // European Journal of Endocrinology. 2006. Vol. 155, N 3. P. 405–414. doi: 10.1530/eje.1.02223
- Mernagh P., Suebwongpat A., Silverberg J., Weston A. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective // Value in Health. 2010. Vol. 13, N 3. P. 180–187. doi: 10.1111/j.1524-4733.2009.00650.x
- Borget I., Bonastre J., Catargi B., et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial // Journal of Clinical Oncology. 2015. Vol. 33, N 26. P. 2885–2892. doi: 10.1200/JCO.2015.61.6722
- Nijhuis T.F., van Weperen W., de Klerk J.M.H. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer // Tijdschrift voor nucleaire geneeskunde. 1999. Vol. 21. P. 98–100.
- Vallejo J.A., Muros M.A. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals // Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2017. Vol. 36, N 6. P. 362–370. doi: 10.1016/j.remnie.2017.09.001
- Luster M., Felbinger R., Dietlein M., Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration // Thyroid. 2005. Vol. 15, N 10. P. 1147–1155. doi: 10.1089/thy.2005.15.1147
- Rosario P.W., Xavier A.C., Calsolari M.R. Recombinant human thyrotropin in thyroid remnant ablation with 131I in high-risk patients // Thyroid. 2010. Vol. 20, N 11. P. 1247–1252. doi: 10.1089/thy.2010.0114
- Iizuka Y., Katagiri T., Ogura K., Inoue M., et al. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer // Annals of Nuclear Medicine. 2020. Vol 34, N 10. P. 736–741. doi: 10.1007/s12149-020-01497-0
- Robbins R.J., Driedger A., Magner J.; The U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine // Thyroid. 2006. Vol. 16, N 11. P. 1121–1130. doi: 10.1089/thy.2006.16.1121
- Tu J., Wang S., Huo Z., et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis // Radiotherapy and Oncology. 2014. Vol. 110, N 1. P. 25–30. doi: 10.1016/j.radonc.2013.12.018
- Ma C., Xie J., Liu W., et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer // Cochrane Database of Systematic Reviews. 2010. doi: 10.1002/14651858.CD008302
- Wolfson R.M., Rachinsky I., Morrison D., et al. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease // Journal of Oncology. 2016. P. 1–6. doi: 10.1155/2016/6496750
- Klubo-Gwiezdzinska J., Burman K.D., Van Nostrand D., et al. Treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin // Thyroid. 2012. Vol. 22, N 3. P. 310–317. doi: 10.1089/thy.2011.0235
- Wolffenbuttel B.H., Coppes M.H., Bongaerts A.H., Glaudemans A.W., Links T.P. Unexpected symptoms after rhTSH administration due to occult thyroid carcinoma metastasis // The Netherlands journal of medicine. 2013. Vol. 71, N 5. P. 253–256.
- Tsai H.C., Ho K.C., Chen S.H., et al. Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal // Diagnostics. 2022. Vol. 12, N 1. P. 221 doi: 10.3390/diagnostics12010221
- Goldberg L.D., Ditchek N.T. Thyroid carcinoma with spinal cord compression // JAMA: The Journal of the American Medical Association. 1981. Vol. 245, N 9. P. 953-954. doi: 10.1001/jama.1981.03310340043025
- Hoelting T., Tezelman S., Siperstein A.E., Duh Q.Y., Clark O.H. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro // Thyroid. 1995. Vol. 5, N 1. P. 35–40. doi: 10.1089/thy.1995.5.35
- Pietz L., Michałek K., Waśko R., et al. Wpływ stymulacji endogennego TSH na wzrost resztkowej objetości tarczycy u chorych po całkowitej tyreoidektomii z powodu raka zróznicowanego tarczycy // Endokrynologia Polska. 2008. Vol. 59. P. 119–122. (In Polish).
- Дедов И.И., Румянцев П.О., Нижегородова К.С., и др. Первый отечественный опыт применения рекомбинантного человеческого тиреотропного гормона при подготовке больных высокодифференцированным раком щитовидной железы к радиойоддиагностике и радиойодаблации // Эндокринная хирургия. 2018. Т. 12, № 3. С. 128–139. doi: 10.14341/serg9806
- Saracyn M., Lubas A., Bober B., et al. Recombinant human thyrotropin worsens renal cortical perfusion and renal function in patients after total thyroidectomy due to differentiated thyroid cancer // Thyroid. 2020. Vol. 30, N 5. P. 653–660. doi: 10.1089/thy.2019.0372
- Chaker L., Razvi S., Bensenor I.M., et al. Hypothyroidism // Nature Reviews Disease Primers. 2022. Vol. 8, N 1. doi: 10.1038/s41572-022-00357-7
- Ortiga-Carvalho T.M., Sidhaye A.R., Wondisford F.E. Thyroid hormone receptors and resistance to thyroid hormone disorders // Nature Reviews Endocrinology. 2014. Vol. 10, N 10. P. 582–591. doi: 10.1038/nrendo.2014.143
- Lien E.A., Nedrebo B.G., Varhaug J.E., et al. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism // Journal of Clinical Endocrinology and Metabolism. 2000. Vol. 85, N 3. P. 1049–1053. doi: 10.1210/jcem.85.3.6439
- Bicikova M., Hampl R., Hill M., et al. Steroids, sex hormone-binding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidism and their changes following thyroid hormone supplementation // Clinical Chemistry and Laboratory Medicine. 2003. Vol. 41, N 3. P. 284–292. doi: 10.1515/CCLM.2003.045
- Lee S.J., Lee H.Y., Lee W.W., Kim S.E. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy // Nuclear Medicine Communications. 2014. Vol. 35, N 7. P. 727–732. doi: 10.1097/MNM.0000000000000118
- Targher G., Montagnana M., Salvagno G., et al. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients // Clinical Endocrinology. 2008. Vol. 68, N 3. P. 481–484. doi: 10.1111/j.1365-2265.2007.03068.x
- Pearce E.N., Wilson P.W., Yang Q., Vasan R.S., Braverman L.E. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort // The Journal of Clinical Endocrinology & Metabolism. 2008. Vol. 93, N 3. P. 888–894. doi: 10.1210/jc.2007-1987
- Ness G.C., Lopez D., Chambers C.M., et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3- methylglutaryl coenzyme A reductase, and apo A-I gene expression // Biochemical Pharmacology. 1998. Vol. 56, N 1. P. 121–129. doi: 10.1016/S0006-2952(98)00119-1
- Pattaravimonporn N., Chaikijurajai T., Chamroonrat W., Sriphrapradang C. Myxedema Psychosis after Levothyroxine Withdrawal in Radioactive Iodine Treatment of Differentiated Thyroid Cancer: A Case Report // Case Reports in Oncology. 2021. Vol. 14, N 3. P. 1596–1600. doi: 10.1159/000520128
- Nagamachi S., Jinnouchi S., Nishii R., et al. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy — analysis by tc-99m-HMPAO and SPM96 // Annals of Nuclear Medicine. 2004. Vol. 18, N 6. P. 469–477. doi: 10.1007/BF02984562
- Constant E.L., De Volder A.G., Ivanoiu A., et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study // Journal of Clinical Endocrinology and Metabolism. 2001. Vol. 86, N 8. P. 3864–3870. doi: 10.1210/jcem.86.8.7749
- Duntas L.H., Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences // European Journal of Endocrinology. 2007. Vol. 156, N 1. P. 13–19. doi: 10.1530/eje.1.02310
- Kao P.F., Lin J.D., Chiu C.T., et al. Gastric emptying function changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy // Journal of Gastroenterology and Hepatology. 2004. Vol. 19, N 6. P. 655–660. doi: 10.1111/j.1440-1746.2003.03326.x
- Botella-Carretero J.I., Prados A., Manzano L., et al. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal // European Journal of Endocrinology. 2005. Vol. 153, N 2. P. 223–230. doi: 10.1530/eje.1.01951
- Duranton F., Lacoste A., Faurous P., et al. Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism // Clinical Kidney Journal. 2013. Vol. 6, N 5. P. 478–483. doi: 10.1093/ckj/sft092
- Coura-Filho G.B., Willegaignon J., Buchpiguel C.A., Sapienza M.T. Effects of thyroid hormone withdrawal and recombinant human thyrotropin on glomerular filtration rate during radioiodine therapy for well-differentiated thyroid cancer // Thyroid. 2015. Vol. 25, N 12. P. 1291–1296. doi: 10.1089/thy.2015.0173
- An Y.S., Lee J., Kim H.K., Lee S.J., Yoon J.K. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients // Scientific Reports. 2023. Vol. 13, N 1. doi: 10.1038/s41598-023-27455-0
- Den Hollander J.G., Wulkan R.W., Mantel M.J., Berghout A. Correlation between severity of thyroid dysfunction and renal function // Clinical Endocrinology. 2005. Vol. 62, N 4. P. 423–427. doi: 10.1111/j.1365-2265.2005.02236.x
- Cho Y.Y., Kim S.K., Jung J.H., et al. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin // Endocrine. 2019. Vol. 64, N 2. P. 293–298. doi: 10.1007/s12020-018-1807-x
- Kreisman S.H., Hennessey J.V. Consistent Reversible Elevations of Serum Creatinine Levels in Severe Hypothyroidism // Archives of Internal Medicine. 1999. Vol. 159, N 1. P. 79–82. doi: 10.1001/archinte.159.1.79
- Mariani L.H., Berns J.S. The Renal Manifestations of Thyroid Disease // Journal of the American Society of Nephrology. 2012. Vol. 23, N 1. P. 22–26. doi: 10.1681/ASN.2010070766
- Kim S.K., Yun G.Y., Kim K.H. et al. Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer // Thyroid. 2014. Vol. 24, N 4. P. 773–777. doi: 10.1089/thy.2013.0110
- Nozu T., Yoshida Y., Ohira M., Okumura T. Severe hyponatremia in association with I (131) therapy in a patient with metastatic thyroid cancer // Internal Medicine. 2011. Vol. 50, N 19. P. 2169–2174. doi: 10.2169/internalmedicine.50.5740
- Shakir M.K., Krook L.S., Schraml F.V., Clyde P.W. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma // Thyroid. 2008. Vol. 18, N 7. P. 787–792. doi: 10.1089/thy.2008.0050
- Al Nozha O.M., Vautour L., How J. Life-threatening hyponatremia following a low-iodine diet: a case report and review of all reported cases // Endocrine Practice. 2011. Vol. 17, N 5. P. e113–e117. doi: 10.4158/EP11045.CR
- Lee J.E., Kim S.K., Han K.H., et al. Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy // PLoS One. 2014. Vol. 9, N 8. P. e106840. doi: 10.1371/journal.pone.0106840
- Horie I., Ando T., Imaizumi M., Usa T., Kawakami A. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma // Endocrine Practice. 2015. Vol. 21, N 5. P. 488–494. doi: 10.4158/EP14532.OR
- Hyer S., Kong A., Pratt B., Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer // Clinical Oncology. 2007. Vol. 19, N 1. P. 83–86. doi: 10.1016/j.clon.2006.11.005
- Riachy R., Ghazal N., Haidar M.B., Elamine A., Nasrallah M.P. Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors // International Journal of Endocrinology. 2020. Vol. 2020. P. 1–7. doi: 10.1155/2020/8649794
- Adramerinas M., Andreadis D., Vahtsevanos K., Poulopoulos A., Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? // Hormones. 2021. Vol. 20, N 4. P. 669–678. doi: 10.1007/s42000-021-00304-3
- Silberstein E. Prevention of radiation sialadenitis and glossitis after radioiodine-131 therapy of thyroid cancer // Journal of Nuclear Medicine. 2007. Vol. 48, Suppl. 2.
- Ma C., Xie J., Jiang Z., Wang G., Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer // European Journal of Nuclear Medicine and Molecular Imaging. 2010. Vol. 37, N 9. P. 1778–1785. doi: 10.1007/s00259-009-1368-6
- Nakada K., Ishibashi T., Takei T. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? // Journal of nuclear medicine. 2005. Vol. 46, N 2. P. 261–266.
- Le Roux M.K., Graillon N., Guyot L. Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study // Head & Neck. 2020. Vol. 42, N 11. P. 3133–3140. doi: 10.1002/hed.26359
- Jentzen W., Balschuweit D., Schmitz J., et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124) I PET(/CT) imaging // European Journal of Nuclear Medicine and Molecular Imaging. 2010. Vol. 37, N 12. P. 2298–2306. doi: 10.1007/s00259-010-1532-z
- Трухин А.А., Ярцев В.Д., Шеремета М.С., и др. Вторичная облитерация слезоотводящих путей при проведении радиойодтерапии 131I дифференцированного рака щитовидной железы // Регуляторные исследования и экспертиза лекарственных средств. 2022. Т. 12, № 4. C. 415–424. doi: 10.30895/1991-2919-2022-12-4-415-424
- Iakovou I., Goulis D.G., Tsinaslanidou Z.,et al. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation // Head & Neck. 2016. Vol. 38, Suppl. 1. P. E227–230. doi: 10.1002/hed.23974
- Rosario P.W., Calsolari M.R. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin // Thyroid. 2013. Vol. 23, N 5. P. 617–619. doi: 10.1089/thy.2012.0050
- Molenaar R.J., Sidana S., Radivoyevitch T., et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer // Journal of Clinical Oncology. 2018. Vol. 36, N 18. P. 1831–1839. doi: 10.1200/JCO.2017.75.0232
- Signore A., Campagna G., Marinaccio J., et al. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation // Journal of Nuclear Medicine. 2022. Vol. 63, N 10. P. 1515–1522. doi: 10.2967/jnumed.121.263442
- Sohn S.Y., Choi J.Y., Jang H.W., et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer // Thyroid. 2013. Vol. 23, N 6. P. 741–747. doi: 10.1089/thy.2012.0136
- Lakshmanan M., Schaffer A., Robbins J., Reynolds J., Norton J. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer // Clinical Nuclear Medicine. 1988. Vol. 13, N 12. P. 866–868. doi: 10.1097/00003072-198812000-00003
- Maxon H.R., Thomas S.R., Boehringer A., et al. Low iodine diet in I-131 ablation of thyroid remnants // Clinical Nuclear Medicine. 1983. Vol. 8, N 3. P. 123–126. doi: 10.1097/00003072-198303000-00006
- Tala Jury H.P., Castagna M.G., Fioravanti C., et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients // Journal of Clinical Endocrinology and Metabolism. 2010. Vol. 95, N 1. P. 230–237. doi: 10.1210/jc.2009-1624
- Lee M., Lee Y.K., Jeon T.J., et al. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas // Thyroid. 2014. Vol. 24, N 8. P. 1289–1296. doi: 10.1089/thy.2013.0695
- Tobey A.E., Hongxiu L., Auh S., et al. Urine iodine excretion exceeding 250 ug/24h is associated with higher likelihood of progression in intermediate and high-risk thyroid cancer patients treated with radioactive iodine [abstract] // Thyroid. 2018. Vol. 28, Suppl. 1. P. A40–A41
- Pluijmen M.J., Eustatia-Rutten C., Goslings B.M., et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma // Clinical Endocrinology. 2003. Vol. 58, N 4. P. 428–435. doi: 10.1046/j.1365-2265.2003.01735.x
- Morris L.F., Wilder M.S., Waxman A.D., Braunstein G.D. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma // Thyroid. 2001. Vol. 11, N 8. P. 749–755. doi: 10.1089/10507250152484583
- Yoo I.D.K.S., Kim S.H., Seo Y.Y., et al. The success rate of initial (131) i ablation in differentiated thyroid cancer: comparison between less strict and very strict low iodine diets // Nuclear Medicine and Molecular Imaging. 2012. Vol. 46, N 1. P. 34–40. doi: 10.1007/s13139-011-0111-y
- Ito S., Iwano S., Kato K., Naganawa S. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer. journal article // Annals of Nuclear Medicine. 2018. Vol. 32, N 6. P. 418–424. doi: 10.1007/s12149-018-1261-0
- Lim C.Y., Kim J.Y., Yoon M.J., et al. Effect of a low iodine diet vs. restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients // Yonsei Medical Journal. 2015. Vol. 56, N 4. P. 1021–1027. doi: 10.3349/ymj.2015.56.4.1021
- Kim H.K., Lee S.Y., Lee J.I., et al. Daily urine iodine excretion while consuming a low-iodine diet in preparation for radioactive iodine therapy in a high iodine intake area // Clinical Endocrinology. 2011. Vol. 75, N 6. P. 851–856. doi: 10.1111/j.1365-2265.2011.04157.x
- Tomoda C., Uruno T., Takamura Y., et al. Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy // Endocrine Journal. 2005. Vol. 52, N 2. P. 237–240. doi: 10.1507/endocrj.52.237
- Sohaimi W.F., Abdul Manap M., Kasilingam L., et al. Randomised controlled trial of one-week strict low-iodine diet versus one-week non-specified low iodine diet in differentiated thyroid carcinoma // Iranian Journal of Nuclear Medicine. 2019. Vol. 27, N 2. P. 99–105.
- Dekker B.L., Links M.H., Muller Kobold A.C., et al. Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients // The Journal of Clinical Endocrinology & Metabolism. 2022. Vol. 107, N 2. P. e604–e611. doi: 10.1210/clinem/dgab691
- Padovani R.P., Maciel R.M., Kasamatsu T.S., et al. Assessment of the Effect of Two Distinct Restricted Iodine Diet Durations on Urinary Iodine Levels (Collected over 24 h or as a Single-Spot Urinary Sample) and Na (+)/I (-) Symporter Expression // European Thyroid Journal. 2015. Vol. 4, N 2. P. 99–105. doi: 10.1159/000433426
- Park J.T., Hennessey J.V. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine // Thyroid. 2004. Vol. 14, N 1. P. 57–63. doi: 10.1089/105072504322783858
- Dekker B.L., Touw D.J., van der Horst-Schrivers A.N.A., et al. Use of Salivary Iodine Concentrations to Estimate the Iodine Status of Adults in Clinical Practice // The Journal of Nutrition. 2021. Vol. 151, N 12. P. 3671–3677. doi: 10.1093/jn/nxab303
Дополнительные файлы
